Join
Live feed
·
PRReleasevia Quantisnow
Larimar Therapeutics Inc. logo

Larimar Therapeutics Announces FDA Clearance to Initiate the 25 mg Cohort of a Phase 2 Dose Exploration Trial of CTI-1601 in Friedreich's Ataxia Patients

ByQuantisnow·Wall Street's wire, on your screen.
LRMR· Larimar Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track LRMR (Larimar Therapeutics Inc.) and more on Quantisnow.